Table I.
Clinical characteristics and treatment outcomes of 39 patients with transitional cell carcinoma of the bladder.
| Characteristics | No. (%) |
|---|---|
| Median age, years (IQR) | 72 (67–80) |
| Median follow-up, months (IQR) | 19 (11–50) |
| Histology | |
| Aberrant differentiation | 11 (28) |
| Adjacent carcinoma in situ | 16 (41) |
| Vascular invasion | 7 (18) |
| Hydronephrosis | 10 (26) |
| Clinical stagea | |
| II | 21 (54) |
| III | 15 (38) |
| IV (N+) | 3 (8) |
| Median prescribed dose of radiation, 2-Gy equivalent (IQR) | 60.0 (60.0–64.0) |
| Chemotherapy | |
| Neoadjuvant | 19 (49) |
| Concomitant | 26 (67) |
| Chemotherapy regimens | |
| Gemcitabine | 22 (56)b |
| Platinum agents | 20 (51)b |
| Fluoropyrimidines | 13 (33) |
| Paclitaxel | 12 (31) |
| Response to therapy | |
| Complete response | 31 (79) |
| Treated with gemcitabine (n=22) | 19 (86) |
| Treated with platinum agent (n=20) | 15 (75) |
| Local recurrence | 8 (21) |
| Non MP-invasive carcinoma (Ta, T1) | 3 |
| Carcinoma in situ (Tis) | 1 |
| MP-invasive carcinoma (T2-4) | 4 |
| Distant metastasis | 11 (28) |
| Total deaths | 22 (61) |
| Bladder cancer deaths | 12 (31) |
a
American Joint Cancer Committee, 7th edition. IQR, interquartile range; MP, micropapillary.
b
The number includes platinum that was administered concomitantly with radiation and not only neoadjuvant.